Drugging RNA–Protein Complexes with Small Molecules to Enable RNA Splice Modulation & Degradation

Time: 9:30 am
day: Conference Day One

Details:

• REM-422 is being developed by Remix Therapeutics for the treatment of ACC and AML/HRMDS

• REMaster™ platform identifies compounds that address undruggable high unmet medical need targets

• Next generation Remix drug discovery programs are enabled by a suite of biophysical assays and expand the scope of pharmacologically tractable splice modulator modalities

Speakers:

Dominic Reynolds
Dominic Reynolds As Chief Scientific Officer, Dominic is stoked to be a part of building Remix from the ground up, leading the design and synthesis of compounds Read more